The company, known for creating the Barbie dolls, has ensured the are taking “immediate action” to fix the mistake ...

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Gossamer Bio (GOSS – Research Report). The associated ...

Gossamer Bio, Inc. ( NASDAQ:GOSS) shareholders will have a reason to smile today, with the analysts making substantial upgrades to next year's statutory forecasts. The consensus estimated revenue ...

Gossamer Bio (GOSS) delivered earnings and revenue surprises of 22.22% and 109.97%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Stock analysts at Barrington Research boosted their FY2024 earnings estimates for VIZIO in a research report issued on ...

As of the latest trading close, GOSS, a Healthcare sector stock, is trading -44.61% below its 52-week high but remains 89.62% above its 52-week low. The Average True Range (ATR) (14 days) of 0.06 ...

Gossamer Bio ( (GOSS)) has released its Q3 earnings. Here is a breakdown of the information Gossamer Bio presented to its investors. Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Gossamer Bio Inc. (GOSS) on Thursday reported a loss of $30.8 million in its third quarter. The San Diego-based company said it had a loss of 14 cents per share.